Sage Therapeutics Ends Collaboration with Biogen on SAGE-324
Sage Therapeutics Ends Collaboration with Biogen
Sage Therapeutics, Inc. (NASDAQ: SAGE), based in Cambridge, has announced that Biogen has decided to terminate its rights under the collaboration and license agreement specifically regarding the SAGE-324 program. This decision follows the recent negative results from the Phase 2 KINETIC 2 Study, which aimed to assess the efficacy of investigational SAGE-324 for chronic treatment of essential tremor (ET). Consequently, both companies have chosen to cease all further clinical development of SAGE-324 in this area.
Continuation of Partnership on ZURZUVAE
Despite the discontinuation of SAGE-324, Sage and Biogen will maintain their partnership on ZURZUVAE® (zuranolone), a significant advancement as the first and only FDA-approved oral treatment specifically aimed at women suffering from postpartum depression (PPD). Both companies are dedicated to their shared mission of enhancing the lives of women affected by PPD and will continue collaborating effectively.
Plans for Future Development of SAGE-324
According to the terms outlined in their collaboration agreement, the termination of the partnership will take effect on a specified date, after which Sage will regain full ownership of the SAGE-324 asset. The company is optimistic about the future and plans to explore other potential indications for SAGE-324 in the coming years.
Important Safety Information for ZURZUVAE
For patients considering ZURZUVAE (zuranolone), it is crucial to note that this medication is classified as a controlled substance (C-IV) due to its potential for abuse and dependence. ZURZUVAE acts as a neuroactive steroid gamma-aminobutyric acid A (GABAA) receptor positive modulator, targeting the treatment of postpartum depression in adults.
When taking ZURZUVAE, patients may experience various common side effects, including drowsiness, dizziness, diarrhea, fatigue, and urinary tract infections. It is advised that individuals do not engage in activities such as driving or operating heavy machinery until 12 hours after the last dose, as their cognitive functions may be impaired.
Insights on SAGE-324
SAGE-324 is an investigational oral neuroactive steroid that serves as a GABAA receptor positive allosteric modulator (PAM). PAMs are designed to enhance the activity of the GABAergic system, the primary inhibitory neurotransmission system within the brain. Although clinical evaluations are ongoing, the safety and efficacy of SAGE-324 have yet to be conclusively determined.
About Sage Therapeutics
Founded in 2010, Sage Therapeutics (NASDAQ: SAGE) is a biopharmaceutical company devoted to developing innovative solutions that enhance brain health. The organization has successfully brought to market the only two FDA-approved treatments targeting postpartum depression. With a robust pipeline, Sage strives to address critical unmet needs in brain health. Located in Massachusetts, the company is committed to pioneering advances that allow every individual to thrive.
Frequently Asked Questions
What led to the discontinuation of the SAGE-324 program?
The discontinuation of the SAGE-324 program was prompted by negative results from the Phase 2 KINETIC 2 Study, which evaluated its effectiveness in treating essential tremor.
How will the end of the collaboration affect ZURZUVAE?
Despite the termination of the partnership on SAGE-324, Sage Therapeutics and Biogen will continue their collaboration on ZURZUVAE® and its applications in treating postpartum depression.
What are the side effects associated with ZURZUVAE?
Common side effects of ZURZUVAE include sleepiness, dizziness, diarrhea, and urinary tract infection. Patients should be cautious regarding their activities after dosage.
What is Sage Therapeutics’ future plan for SAGE-324?
Sage Therapeutics plans to fully regain ownership of the SAGE-324 asset and will continue to explore potential indications for its use moving forward.
What is the mission of Sage Therapeutics?
Sage Therapeutics aims to pioneer innovative solutions and provide life-changing brain health medicines to empower every individual to thrive.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- SUPCON Showcases Innovative Solutions at KIOGE 2024
- Market Movements Ahead: Consumer Spending and Inflation Trends
- Thailand's Pension Fund Allocates $11.6 Billion for Global Assets
- Southwest Airlines Launches Major $2.5 Billion Stock Buyback
- IonQ Secures $54.5 Million U.S. Air Force Quantum Contract
- Quality Collision Group Collaborates on New Body Shop Project
- Tencent Music Showcases Commitment to Sustainability with ESG
- AIRAmed and Memory Treatment Centers Collaborate on Alzheimer’s Research
- Vantage Foundation and V&A Solution Create Joyful Learning Event
- Vantage Foundation and V&A Solution Host Enriching Children's Event
Recent Articles
- Virtu Financial Celebrates Exceptional Women in Finance Leaders
- Eyenovia Introduces Clobetasol for Ocular Surgery Relief
- Strategic Alliance to Elevate Ready-to-Use Solutions in Pharma
- Key Carbon and Marex Group Collaborate on Carbon Initiatives
- BankID BankAxept Moves Forward with Criipto Acquisition Strategy
- Promising Results for Pasithea's PAS-004 in Advanced Cancer Trials
- Aethon United Completes Tender Offer for Senior Notes Successfully
- Goliath Resources Expands Financing to Over $16 Million
- Telehealth Satisfaction Study Reveals Varied Patient Experiences
- BlackRock and Santander Strengthen Ties for Project Financing
- N-able Achieves Triple Win in Workplace Culture Awards
- Celebrating 20 Years of Profit Launch Workshops for Contractors
- Monex Canada Strengthens Team with Key Appointments for Growth
- Truist Foundation Commits $500,000 for Hurricane Relief Efforts
- Marqeta Partners with Found for Enhanced Business Solutions
- Sekur Private Data Ltd. Expands into Latin America Market
- Everseen's Innovative Vision AI Drives Remarkable Retail Growth
- Innovative AI Tool Launches to Safeguard Nature in Development
- Unveiling the AI-Driven Nature Risk Tool by AECOM and SMI
- VersaBank Celebrated for Innovation in Banking Technology
- Discover Purcell Properties at the Dublin Property Expo
- Investing in Growth: New State Capital Partners and Expo Group
- Discover the Latest Innovations from Descartes at Industry Forum
- Freightos Partners with HNA Cargo to Enhance Air Cargo Services
- Market Gains on Micron's Surge and China’s Stimulus Moves
- Exciting Deals Await: Join Wayfair's Holiday Way Day Sale!
- Southwest Airlines Launches Exciting New Transformation Plan
- Experience Stunning Clarity with TrueCut Motion Technology
- Zefr Expands Brand Safety Features to Tackle Misinformation
- Big Lots Launches Affiliate Program for Influential Creators
- Celebrating Innovation: Garmin Health Awards Highlight Progress
- Innovative Solutions for Accelerating Building Decarbonisation
- Join the Movement to Free Edwin Rubis from His Sentence
- Enhancements in Keeper Security's iOS Autofill Capabilities
- Elevate Your Coffee Experience This National Coffee Day
- CEO Warrior Highlights Lifelong Learning at Upcoming Event
- Southwest Airlines Introduces Innovative Plan to Enhance Growth
- Southwest Airlines Welcomes Robert Fornaro to Its Board
- WeBank and Oliver Wyman Examine Digital Banking Trends Globally
- Descartes Systems Group Reveals Innovations for Supply Chain 2024
- B. Riley Predicts Bright Future for InfuSystems as Growth Looms
- HSBC Analysts Forecast Potential Fed Rate Hikes by 2026
- Amazon’s Future: Embracing AI and Revamping Corporate Culture
- ANI Pharmaceuticals Launches FDA-Approved Ketoconazole Shampoo
- AECOM Secures Major Contract for Zero Emission Bus Initiative
- NextRNA Therapeutics Welcomes Jesse Smith, PhD as CSO
- Teleflex Set to Showcase Barrigel Rectal Spacer at ASTRO Meeting
- Hut 8 Launches Exciting GPU-as-a-Service Offering
- PureTech Systems Secures Landmark AI Contract for Waterway Safety
- X's Transparency Report Reveals Significant Account Suspensions